Pfizer's Ibrace failed an early-stage breast cancer trial

Pfizer's oral CDK4/6 inhibitor Ibrace failed to reach the primary endpoint of improved noninvasive survival (iDFS) for early breast cancer, thus losing opportunities in complementary therapy.The results came from the PENELOPE-B III clinical trial, which evaluated Palbociclib surgical chemotherapy in women with Hollyoos positive (HR plus), human epithelial growth factor negative (HER2-) early breast cancer, and pre-immersion residual immersion disease.The trial compared one year of Ibrace treatment plus at least five years of standard assisted endocrine therapy with at least five years of standard assisted endocrine therapy.Pfizer did not disclose the full data in a statement, but added that details of the PENELOPE-B study will be announced at an upcoming medical conference.

the United States, Ibrance has been approved for the treatment of adult patients with advanced or metastatic breast cancer in HR plus, HER2, in combination with aromatase inhibitors as an initial endocrine treatment for post menopenerial women or men.Chris Boshoff, Chief Development Officer, Oncology, Pfizer Global Product Development, said, "
is the first randomized Phase
III study to establish mature iDFS results for CDK4/6 inhibitors as part of early-stage breast cancer-assisted treatment.added: "While we are disappointed with this result, we hope to continue to work with our research partners to understand the subgroup data and how it will provide information for the development of our next generation of CDK inhibitors in early breast cancer." Pfizerhope that the treatment would show early potential in high-risk populations, although that hope seems to have finally been shattered.
（cyy123.com）